Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
AssigneeTakeda GmbH
InventorsThomas WAGNER, Malin CARLSSON, Margit STAUM KALTOFT
Life of this patent
Estimating the term…
Abstract
The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
Claims27
1-72. (canceled)
A neutralizing antibody or a functional fragment thereof specifically binding primate GM-CSF for use in the treatment of an inflammatory disease selected from a group comprising rheumatoid arthritis, SLE, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and osteoarthritis,
- wherein the neutralizing antibody or a functional fragment thereof specifically binding primate GM-CSF is used according to the following dosing scheme:
- (i) a first initial dose,
- (ii) followed by administration of a second dose within a period of 7-21 days after the first initial dose,
- (iii) at least one further dose administered within a period of 21-35 days after said second dose,
- (iv) optionally followed by further doses administered within intervals of 21-35 days.
A neutralizing antibody or a functional fragment thereof specifically binding primate GM-CSF for use in the treatment of an inflammatory disease selected from a group comprising rheumatoid arthritis, SLE, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and osteoarthritis,
- wherein the neutralizing antibody or a functional fragment thereof specifically binding primate GM-CSF is used according to the following dosing scheme:
- (i) a first initial dose,
- (ii) followed by administration of a second dose within a period of 7-21 days after the first initial dose,
- (iii) at least one further dose administered within a period of 21-35 days after said second dose,
- (iv) optionally followed by further doses administered within intervals of 21-35 days,
- wherein the patients are selected from the following patient subgroups:
- a-1) Patients not treated for an inflammatory disease selected from a group comprising rheumatoid arthritis, SLE, psoriatic arthritis, or osteoarthritis, or
- a-2) Patients not treated for pain associated with a group of inflammatory diseases comprising rheumatoid arthritis, SLE, psoriatic arthritis, or osteoarthritis, or
- a-3) Patients treated for an inflammatory condition.
Dependencies are inferred from the claim text.